Literature DB >> 28678146

Contrast-induced kidney injury: how does it affect long-term cardiac mortality?

Alessandro Andreis1, Carlo Budano, Mario Levis, Paolo Garrone, Tullio Usmiani, Fabrizio D'Ascenzo, Ovidio De Filippo, Maurizio D'Amico, Laura Bergamasco, Luigi Biancone, Sebastiano Marra, Antonio Colombo, Fiorenzo Gaita.   

Abstract

AIMS: Contrast-induced acute kidney injury (CIAKI) is a common complication after coronary angiography or percutaneous revascularization (PCI). This study aimed to investigate the association of CIAKI with long-term cardiovascular adverse events.
METHODS: In total, 980 patients undergoing coronary angiography/PCI were assessed in this prospective cohort study. The primary endpoint was major adverse cardiac and cerebrovascular events (MACCE) and cardiac death (CVD) during an 8-year follow-up. Glomerular filtration rate change during the follow-up was the secondary endpoint.CIAKI was defined as a serum creatinine increase at least 0.3 mg/dl in 48 h or at least 50% in 7 days.
RESULTS: CIAKI was observed in 69 patients (7%). Chronic kidney disease [relative risk (RR) = 4, P < 0.01], reduced ejection fraction (RR = 2.88, P < 0.01), CIAKI risk score at least 4 (RR = 2.64, P = 0.02), and emergency coronary angiography/PCI (RR = 3.87, P < 0.01) increased CIAKI risk, whereas statins were protective (RR = 0.32, P < 0.01).Patients with CIAKI had higher rates of 8-year cardiovascular adverse events: 54 versus 15% MACCE (RR = 6.67, P < 0.01), 38 versus 4% CVD (RR = 15.73, P < 0.01). Among other factors, CIAKI was the strongest predictor of 8-year MACCE (RR = 3.16, P < 0.01) and CVD (RR = 7.34, P < 0.01).During the follow-up, glomerular filtration rate declined drastically in CIAKI patients: 70 versus 39% had chronic kidney disease stage worsening (P < 0.01) and 8 versus 0.3% started hemodialysis (P < 0.01).
CONCLUSION: We found a strong correlation between CIAKI and poor long-term cardiac outcomes. Apparently showing up as a transient, functional impairment of kidney function, CIAKI implies an organic damage with structural modifications leading to significant kidney deterioration over time, responsible for an increased risk of long-term cardiac events. Statins significantly reduced CIAKI occurrence. A careful management of high-risk patients is needed to limit long-term complications of coronary angiography/PCI.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28678146     DOI: 10.2459/JCM.0000000000000543

Source DB:  PubMed          Journal:  J Cardiovasc Med (Hagerstown)        ISSN: 1558-2027            Impact factor:   2.160


  4 in total

1.  Sometimes neither water nor fire are more useful than friendship-a new risk score for prediction of contrast-induced nephropathy (CIN) and long-term adverse outcomes in patients undergoing coronary angiography.

Authors:  Ovidio De Filippo; Fabrizio D'Ascenzo; Francesco Piroli; Carlo Budano; Gaetano Maria De Ferrari
Journal:  J Thorac Dis       Date:  2019-07       Impact factor: 2.895

2.  Contrast Induced Acute Kidney Injury and its Impact on Mid-Term Kidney Function, Cardiovascular Events and Mortality.

Authors:  Werner Ribitsch; Joerg H Horina; Franz Quehenberger; Alexander R Rosenkranz; Gernot Schilcher
Journal:  Sci Rep       Date:  2019-11-15       Impact factor: 4.379

3.  Evaluation of Crocin Effect on Contrast-Induced Nephropathy Following Coronary Angiography or Angioplasty: A Randomized Controlled Trial.

Authors:  Lida Shojaei; Shima Esfandiary; Mohammad Rouzbahani; Fatemeh Heydarpour; Mostafa Bahremand; Reza Heidary Moghadam; Ghazal Mahmoudi; Farzaneh Korani; Farshid Raissi; Foroud Shahbazi
Journal:  Iran J Pharm Res       Date:  2022-06-14       Impact factor: 1.962

4.  Contrast Associated Acute Kidney Injury and Mortality in Older Adults with Acute Coronary Syndrome: A Pooled Analysis of the FRASER and HULK Studies.

Authors:  Rita Pavasini; Matteo Tebaldi; Giulia Bugani; Elisabetta Tonet; Roberta Campana; Paolo Cimaglia; Elisa Maietti; Giovanni Grazzi; Graziella Pompei; Gioele Fabbri; Alessio Fiorio; Andrea Rubboli; Gianni Mazzoni; Francesco Vitali; Matteo Serenelli; Gianluca Campo; Simone Biscaglia
Journal:  J Clin Med       Date:  2021-05-16       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.